TY - JOUR
T1 - Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
AU - Kralovics, Robert
AU - Teo, Soon Siong
AU - Buser, Andreas S.
AU - Brutsche, Martin
AU - Tiedt, Ralph
AU - Tichelli, Andre
AU - Passamonti, Francesco
AU - Pietra, Daniela
AU - Cazzola, Mario
AU - Skoda, Radek C.
PY - 2005/11/15
Y1 - 2005/11/15
N2 - We identified 13 new gene expression markers that were elevated and one marker, ANKRD15, that was down-regulated in patients with polycythemia vera (PV). These 14 markers, as well as the previously described PRV1 and NF-E2, exhibited the same gene expression alterations also in patients with exogenously activated granulocytes due to sepsis or granulocyte colony-stimulating factor (GCSF) treatment. The recently described V617F mutation in the Janus kinase 2 (JAK2) gene allows defining subclasses of patients with myeloproliferative disorders based on the JAK2 genotype. Patients with PV who were homozygous or heterozygous for JAK2-V617F exhibited higher levels of expression of the 13 new markers, PRV1, and NF-E2 than patients without JAK2-V617F, whereas ANKRD15 was down-regulated in these patients. Our results suggest that the alterations in expression of the markers studied are due to the activation of the Jak/signal transducer and activator of transcription (STAT) pathway through exogenous stimuli (sepsis or G-CSF treatment), or endogenously through the JAK2-V617F mutation.
AB - We identified 13 new gene expression markers that were elevated and one marker, ANKRD15, that was down-regulated in patients with polycythemia vera (PV). These 14 markers, as well as the previously described PRV1 and NF-E2, exhibited the same gene expression alterations also in patients with exogenously activated granulocytes due to sepsis or granulocyte colony-stimulating factor (GCSF) treatment. The recently described V617F mutation in the Janus kinase 2 (JAK2) gene allows defining subclasses of patients with myeloproliferative disorders based on the JAK2 genotype. Patients with PV who were homozygous or heterozygous for JAK2-V617F exhibited higher levels of expression of the 13 new markers, PRV1, and NF-E2 than patients without JAK2-V617F, whereas ANKRD15 was down-regulated in these patients. Our results suggest that the alterations in expression of the markers studied are due to the activation of the Jak/signal transducer and activator of transcription (STAT) pathway through exogenous stimuli (sepsis or G-CSF treatment), or endogenously through the JAK2-V617F mutation.
UR - http://www.scopus.com/inward/record.url?scp=25844432737&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=25844432737&partnerID=8YFLogxK
U2 - 10.1182/blood-2005-05-1889
DO - 10.1182/blood-2005-05-1889
M3 - Article
C2 - 16081684
AN - SCOPUS:25844432737
VL - 106
SP - 3374
EP - 3376
JO - Blood
JF - Blood
SN - 0006-4971
IS - 10
ER -